Tech Company Financing Transactions
Sonoma Biotherapeutics Funding Round
8VC, Arch Venture Partners and Lyell Immunopharma participated in a $40 million Series A venture round for Sonoma Biotherapeutics. The round was announced by the company on 2/10/2020.
Transaction Overview
Company Name
Announced On
2/10/2020
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
This partnership will further enable Sonoma's rapid translation of Treg therapies from target identification and discovery, through preclinical and clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 E. Jamie Ct. 250
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Best-in-class regulatory T cell therapy, delivering long-lasting, highly effective, curative treatments across a spectrum of autoimmune and degenerative diseases. Founded by pioneers in regulatory T cell therapy, Sonoma brings together next-generation research, development and manufacturing capabilities in cell therapy and genetic engineering.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 2/7/2020: Netskope venture capital transaction
Next: 2/10/2020: SaaSWorks venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs